Aiforia Technologies Oy Class A · OMXHEX:AIFORIA
Aiforia Technologies Oy Class A — H1 2026 Earnings Presentation
20 slides from Aiforia Technologies Oy Class A's earnings presentation, Aug 28, 2026
Slide 1: Aiforia - AI for image analysis
. @ aifor Al for image analysis
Slide 2: Financing arrangements and new customers support future growth, revenue remained below comparison period
Financing arrangements and new customers support future growth, revenue remained below the comparison period's level Half-Year Financial Report for January 1 - June 30, 2026 Aiforia Technologies Plc August 28, 2026
Slide 3: Today's agenda
Today’s agenda 01. Business highlights Jukka Tapaninen 02. Financial review CEO 03. Q&A Antti Ojala CFO August 28, 2026 | Half-Year Financial Report, January 1–June 30, 2026 3
Slide 4: H1 2026 highlights
H1 2026 highlights Expansion to five new AP-HP hospitals in France with CE-IVD-marked prostate cancer diagnostics solution. Winning a public tender to provide AI-assisted diagnostic solutions to a regional healthcare provider in Spain. Expansion of partner network, such as the collaboration with Pros
Slide 5: Most significant clinical accounts
Most significant clinical A regional healthcare provider, Spain ● Breast and prostate cancer diagnostics accounts Assistance Publique-Hôpitaux De Paris (AP-HP), France ● ● Prostate cancer diagnostics 1) Bicêtre, 2) Saint-Louis, 3) Cochin, 4) Hôpital Européen Georges Pompidou (HEGP), 5) La Pitié Salpé
Slide 6: Revenue generation over time – two models
Revenue generation over time – two models “Right to Access” customer Utilization (Aiforia-hosted cloud) begins Fees from AI model #2 Fees from AI model #1 Deployment phase 1–2 months (existing customer) 3 months – over 1 year (early-stage digital customer) Utilization “Right to Use” customer begins
Slide 7: Market is growing
Market is growing Surging global cancer burden combined with an acute pathologist workforce deficit GLOBAL CANCER BURDEN WORKFORCE DEFICIT DIAGNOSTIC DEMAND +67% 4,230 >50% Projected growth in annual Projected FTE pathologist Increase in diagnostic case global cancer cases shortage in US complexity A
Slide 8: Aiforia's expanding role across the digital pathology workflow
Aiforia's expanding role across the digital pathology workflow World digital pathology market: USD 1 billion in 2023, growing toward an estimated USD 2 billion by 2029 Scanning & Image management & AI supported Prognostic & digitalization workflow orchestration Image Analysis predictive AI USD 449M ->
Slide 9: Aiforia's product portfolio is expanding
Aiforia® Lung Cancer Suite: PD-L1* Aiforia's product Aiforia® Breast Cancer Suite: Aiforia® Lymph Node Metastasis* portfolio is ER*, PR*, Ki67*, HER2*, Grading*, Lymph Node Metastasis* expanding Aiforia® Gastric Suite Aiforia® Colon Suite: Aiforia® Gastric Cancer*, H. pylori Lymph Node Metastasis*,
Slide 10: Investments in growth and sales capabilities
Investments in growth and sales capabilities Team restructuring and Targeted recruitments sales process changes ● New Chief Commercial Officer starting ● Establishing Customer Success team to in September drive retention & account expansion ● Appointing regional Account Executives ● Scaling channel s
Slide 11: Mid-term business targets
Mid-term business targets Achieve financial independence by the end of 2027 Create a product offering that covers 80% of the pathologist’s diagnostic workflow (2030) Achieve 50 key accounts (potential for over 500 EUR thousand in annual recurring revenue) (2030) Leverage technology beyond diagnostic s
Slide 12: Financial review
2 Financial review August 28, 2026 | Half-Year Financial Report, January 1–June 30, 2026 12
Slide 13: H1 2026 results in brief
H1 2026 results in brief 18% EUR 2,891 (3,679) thousand investment mainly in Group revenue was EUR 753 (1,395) thousand product development EBITDA was EUR -4,726 (-3,014) thousand* Finland EBIT was EUR -7,623 (-5,403) thousand 24% Europe Number of employees on average 68 (69) 43% and other 33% Cash
Slide 14: H1 2026: Stable order book compared to year end
H1 2026: Stable order book compared to year end Order book EUR, million 6 -32% ● Order book at the end of review period EUR 5.1 5 3.5 million (5.1), decrease of 32% from the 0.9 comparison period. 4 3.4 3.5 ● Order book at the same level as on 3 0.6 0.7 December 31 2025. 4.2 ● Part of the order book
Slide 15: H1 2026: Revenue decreased by 46%
H1 2026: Revenue decreased by 46% EUR, thousand ● January–June revenue decreased by 46% and 2,000 totaled EUR 753 (1,395) thousand. ● Clinical revenue decreased by 57% in 1,500 1,395 January–June. However, EUR 2.8 million, i.e. 80% of the order book, is clinical. 597 1,000 -46% ● Revenue negatively
Slide 16: Financing agreement with the EIB to support the execution of our growth strategy
Financing agreement with the EIB to support the execution of our growth strategy 18% ● A venture debt financing arrangement of up to EUR 20 million with the European Investment Bank ("EIB"), signed on July 31, 2026. ● Three loan tranches; first loan tranche EUR 5 million, the second EUR 7 million, and
Slide 17: Q&A
3 Q&A 17
Slide 18: For more information
For more Investor Relations Contacts information Jukka Tapaninen, CEO jukka.tapaninen@aiforia.com, +33 61 041 6686 www. investors.aiforia.com ir@aiforia.com Antti Ojala, CFO antti.ojala@aiforia.com, +358 40 720 2448
Slide 19: Disclaimer
Disclaimer It should be noted that Aiforia and its business are exposed to various risks and uncertainties, and certain statements herein which are not historical facts, including without limitation, those regarding expectations for market growth and developments; expectations for growth and profitab
Slide 20: Aiforia - AI for image analysis
. @ aifor Al for image analysis 20